Microsoft Word - web.docx
|
|
|
- きみえ よしくに
- 5 years ago
- Views:
Transcription
1 12 10 E 16:30 17:30 : ( ) " " ( ) :50 16:20 A 1 ( ) ( ) B ( ) ( ) D ( ) (
2 12 11 B 10:00 12:00 " " ( ) ( ) 2
3 (10 ) A 1 ( ) 8:30 12:40 8:30 9:20 1 ( ) 1A-01 Cannabidiol-2',6'-dimethyl ether ( 1, 2, 3 ) 1, 1, 1, 2, 3, 1 1A-02 ( 1 2, 3, 4 ) 1, A-03 ( ),,,,,, 1A-04 Ca ( 1, 2, 3 ) 1, 2, 2,3, 1, 3, 2,3 9:20 10:15 2 ( ) 1A-05 β- ( ),,,, 1A-06 / ( ),,,, 1A-07 ( 1, 2, 3 ) 1, 1,2, 1,2, 1, 1,3, 1,2 1A-08 ( 1, 2, 3 ) 1, 1, 1, 1,2, 1, 1,2, 1,2, 1,3, 1,2 10:15 11:10 3 1A-09 ( 1, 2 ) 1, 1, 2, 2, 1 1A-10 CYP3A4 ( ),, 1A-11 ( 1, 2, 3, 4 ) 1, 2, 3, 4, 2, 2, 2 1A-12 ( 1, 2 ) 1, 2, 2, 2, 2, 2, 2 11:10 12:00 4 ( ) 1A-13 ATF4 ( ),,, 3
4 , 1A-14 Ampicillin/sulbactam ( 1, 2, 3, 4, 5 ) 1, 2,,,, 4, 4, 1, 2, 5, 1,2 1A-15 Alport p53 (, COE ) 1,2, 1,2, 1,2, 1,2, 1,2, 1,2, 1,2 1A-16 EGFR-tyrosine kinase ( 1, 2, 3, ) 1, 1,2, 3,, 1,2 12:00 12:40 5 ( ) 1A-17 PK-PD ( 1, 2, 3, 4, 5 ) 1, 2, 1, 2, 2, 2, 3, 3, 4, 4, 5, 1, 2 1A-18 /α- NF-κB decoy ( ),,, 1A-19 ( ),,,,,, B ( ) 8:30 12:25 8:30 9:20 1 ( ) 1B-01 UDP-glucuronosyltransferase 1A9 2B7 cytochrome P450 3A4 ( 1, 2, 3, 4 ) 1, 1, 1, 2, 3, Peter I. Mackenzie 4, 1 1B-02 IL-4/IL-13 M2, APP23 ( ),,, 1B-03 Myosin 1E ( ),,,, 1B-04 β GRK5/ β 2,,,, 9:20 10:15 2 ( ) 1B-05 PGG ( 1, 2, 3 ) 1, 2, 1, 3, 2, 1 1B-06 MIP-T3 ( ),, 1B-07 physical medicine( 1, 4
5 COE 2 ) 1,2, 1,2, 1,2, 1,2, 1,2, 1,2, 1,2, 1,2, 1,2 1B-08 liver PPARγ-dependent gene 1 ( 1, 2 ) 1, 1, 2, 1 10:15 11:20 3 ( ) 1B-09 SIRT1 ( 1, 2, 3 ) 1, 1, 2, 1, 3,,,,, 1B-10 ( ),, 1B-11 ( ),, 1B-12 HIV-1 Nef ( 1, 2 ) 1, 1, 1, 1, 2, 1 1B-13 HIV HIV ( 1, 2, 3 ) 1, 1, 3, 1,3, 3, 1, 1, 1,2 11:20 12:25 4 ( ) 1B-14 HIV ( 1, 2 ) 1, 1, 1, 1,2, 1 1B-15 HIV ( 1, 2 ) 1, 1, 1, 1, 1,2, 1 1B-16 N ( 1, COE 2, 3, 4, 5 ) 1,2, 1,2,3, 1,2, 1,2, 4, 5, 1,2, 1,2, 1,2 1B-17 UDP- ( ),,, 1B-18 ( ), C ( ) 8:30 12:30 8:30 9:20 1 ( ) 1C-01 ( ),,, 1C-02 ( ),,, 1C-03 5 ( 1, 2, 3 ) 1, 1, 1, 2, 2, 3, 1 5
6 1C-04 DNA2 ( ), 9:25 10:20 2 ( ) 1C ( ), 1C-06 p53-mdm2 ( ),, 1C-07 Ubc13-Uev1A Lissodendryx fibrosa ( ),,, 1C-08 Lewis Ar-DIOPO ( 1, 2 ) 1, 1, 1, 2, 1, 1 10:25 11:15 3 ( ) 1C-09 ( 1, 2 ) 1, 2, 1, 1 1C-10 ( ) Clausenamide ( ),,,, 1C-11 ( ),,,, 1C-12 ( 1, 2 ) 1, 2,, 1 11:20 12:30 4 ( ) 1C-13 P-, ( ),,, 1C-14 (Spondylus sp.) (PBDE-OH) O- ( 1, 2 ) 1, 1, 2, 1 1C-15 ( 1, 2, 3, 4 ) 1, 2, 3, 3, 1, 1, 4, 3, 1, 3 1C-16 E-Z ( 1, 2 ) 1, 1, 2, 1, 1 1C-17 C2 ( 1, 2 ) 1, 1, 2, 1, 1 D ( ) 8:30 12:10 8:30 9:10 1 ( ) 1D-01 ( 1, 2, 3, 4, 5 ) 1,, 1, 1, 3, 4, 5, 5, 1 1D-02 dihydropyrazine -3( ),,, 6
7 1D-03 dihydropyrazine -4( ),,, 1D-04 9:10 10:00 2 ( ) 1D-05 ( ),,,, 1D-06 ( ),,,,, 1D-07 ( 1, 2, 3 ) 1,, 3, 2, 2, 2 1D-08 ( ),, 10:00 10:55 ( ) 1D-09 7-N,N- FRET ( ),,,,, 1D-10 HPLC ( ),,,,,,, 1D-11 ( 1, 2 ) 1, 2, 1, 2 1D-12 [15] ( ),,,,, 10:55 11:45 4 ( ) 1D-13 ( ),,,,,, 1D-14 (F4H11OH) DPPC ( ),,,,, 1D-15 ( ),, 1D-16 ( ),, 11:45 12:1= 5 ( ) 1D-17 ESR MRI ( ),, 1D-18 In vivo ESR ( ),, 7
8 (10 ) A-1 ( ) 13:30 15:40 13:30 14:50 6 ( ) 1A-20 ( ),,,,,,, 1A-21 ( ),,,,,,, 1A-22 ( ),,,, 1A-23 Factor X/Factor Y ( ),,,, 1A-24 3(AQP3) ( ),,, 1A-25 ( ),,,, 14:50 15:40 7 ( ) 1A-26 ( 1, GSM 2 ) 1, 1, 1, 2, 1, 1, 1, 1, 1 1A-27 MRSA PK-PD ( ),,,, 1A-28 ( 1, 2 ) 1, 1, 2, 2, 1,2 1A-29 ( ),,, B ( ) 13:30 14:55 13:30 14:10 5 ( ) 1B-19 FM3A ( ),,, 1B-20 liver PPARγ-dependent gene 3 ( 1, 2 ) 1, 1, 1, 2, 1 1B-21 liver PPARγ-dependent gene 2 ( 1, 2 ) 1, 1, 1, 2, 1 1B-22 PI3K ( 1, 2, 3 ) 1, 2, 3, 1, 1, 1, 1 8
9 14:15 14:55 6 ( ) 1B-23 ( ),,,,,,, 1B-24 Inhibition of HIV-1 Preotease Expression in T cells Using CD4 aptamer sirna Chimeras( 1, COE 2 ) 1, 1, 1, 1,2 1B-25 NC (, ) 1,,,,,,,,,,, 1B-26 ( ),,,,,,,, C ( ) 13:30 15:40 13:30 14:35 5 ( ) 1C-18 A ( ),,, 1C-19 cmc-a ( 1, 2 ) 1, 1, 1, Jacques Eustache 2, 1 1C-20 ( ),,, 1C-21 Conia- ( ),,, 1C-22 ( ),,, 14:35 15:40 6 ( ) 1C-23 -exo- ( ),,, 1C-24 4 ( 1, 2, 3 ) 1, 1, 1, 2, 2, 3, 1 1C-25 β- ( 1, 2 ) 1, 2, 1, 2, 1 1C-26 -, Oppositinine A B ( ),, 1C-27 Jolkinolide ( 1, 2 ) 1, Guo-Wei Qin, 1, 1 D ( ) 13:30 15:40 13:30 14:35 6 ( ) 1D-19 ( ) Xanthatin 1 GADD45γ ( 1, 2, 3 ) 1, 1, 2, 1, 3, 1 9
10 1D-20 ( ) Xanthatin 2 IIα ( 1, 2, 3 ) 1, 1, 2, 1, 3, 1 1D-21 2,2',4,5'-tetrabromobiphenyl(BB49) in vitro ( ),,,,,,, 1D-22 TCDD prolactin ( 1, 2, 3 ) 1, 1, 1, 1, 1, 2, 3, 2, 1 1D-23 2,3,7,8-Tetrachlorodibenzo-p-dioxin ( 1, 2 ) 1, 1,2, 1, 1, 1 14:35 15:40 7 ( ) 1D-24 dihydropyrazine -1( ),,, 1D-25 dihydropyrazine -2( ),,,, 1D-26 MDMA Detection window ( ),,,, 1D-27 HPLC- ( ),,,,,, 1D-28 ( 1, 2, 3 ) 1, 1, 1, 2, 3, 1, 1, 2, 2, 1 2 (11 ) A 1 ( ) 8:30 12:40 8:30 9:35 8 ( ) 2A-01 (H12(ADP) ) ( 1, 2, 3, 4, 5 ) 1, 1, 1,2, 3, 3, 3, 3, 4, 1,2, 5, 1, 2 2A-02 - ( 1, 2, ) 1, 1, 1,2, 1, 1,2, 1, 1,3, 1,2 2A-03 ( 1, 2, 3 ) 1, 1, 1,2, 1,2, 1,3, 1,2 2A-04 ESI-TOF/MS ( 1, 2, 3, 4, 5 ) 1, 1, 1,2, 1,2, 3, 4, 1,5, 1,2 10
11 2A-05 ( ),, 9:35 10:40 9 ( ) 2A-06 ( 1, 2, 3, 4, 5 ) 1, 2, 3, 4, 4, 4, 5, 5, 2, 2, 2 2A-07 ( 1 ) 1, 1, 1, 1 2A-08 C / E (CME) ( 1, 2, 3 ) 1, 1, 1, 1, 1, 1, 1 2A-09 Smad4 ( ),,,,, 2A-10 VDR ( ),,,,,, 10:40 11:30 10 ( ) 2A-11 ( ),,,, 2A-12 Pemetrexed (Alimta) ( ),,, 2A-13 physical medicine ( 1, COE 2 ) 1,2, 1,2, 1,2, 1,2, 1,2, 1,2, 1,2 2A-14 alport physical medicine ( 1, COE 2 ) 1,2, 1,2, 1,2, 1,2, 1,2, 1,2, 1,2, 1,2, 1,2 11:30 12:40 11 ( ) 2A-15 2 ( ),,, 2A β- ( 1 DDS 2 ) 1, 1, 1, 2, 1 2A-17 ( 1 2 ) A-18 ( ),,,,, 11
12 2A-19 BAY , ( 1, 2, 3, 4, 5 ) 1, 1,, 3, 2,4, 5, 1 A 2 ( ) 8:30 10:15 8:30 9:20 12 ( ) 2A-20 PK/PD ( 1, 2 ) 1, 2, 1, 2, 1 2A-21 ABCG2 mirna ( ),,,, 2A-22 PCFT 5' SNPs ( ),, 2A-23 DPYD mirna ( ),, 9:20 10:15 13 ( ) 2A-24 ( 1, 2 ) 1,, 1, 1,,, 1 2A-25 AMPK-SREBP ( 1, 2 ) 1, 2, 2, 2, 2, 2, 1,2, 2 2A-26 ( ),,,,,,, 2A-27 ( ),,,,,,,,, B ( ) 8:30 9:40 8:30 9:35 7 ( ) 2B-01 ERK-MAP ( ),,, 2B-02 ( 1, 2 ) 1, 1, 1, 1, 1, 1, 2, 1 2B-03 [2]Rotaxane ( ),,, 2B-04 poly ADP ribose polymerase olaparib T ( 1, 2 ) 1, 1, 2, 1 2B-05 (, 2, 3 ),,,,, 2, 3 12
13 , C ( ) 8:30 12:15 8:30 9:35 7 ( ) 2C-01 2' C4' DNA ( ),,,,, 2C-02 1,4- ( ),, 2C-03 2' C4' ( ),,, 2C-04 ( ), John Brazier,, 2C-05 3 DNA 1'-1'- ( ),,, 9:35 10:40 8 ( ) 2C-06 Garlic Sulfoxide (10)( ),, 2C-07 Garlic Sulfoxide (11)( ),, 2C-08 (146) Solanum jasminoides ( ),, 2C-09 ( 1, 2, 3 ) 1, 1, 1, 2, 2, 3, 3, 3, 3, 1, 1 2C-10 ( 1, 2, 3 ) 1, 1, 1, 2, 2, 3, 3, 1 10:40 11:20 9 ( ) 2C-11 Pachypell Manzamine ( 1, 2 ) C-12 [2.2.2] notoamide ( ),,, 2C-13 ( 1, 2 ) 1,, 1, 1 11:20 12:10 10 ( ) 2C-14 ( 1, 2 ) 1, 2C-15 Morita-Baylis-Hillman ( 1, 2 ) 1, 2C-16 ( 1, Department of Chemistry, University of Pittsburgh 2 ) 1,2, 2 13
14 2C-17 6 ( 1, 2 ),,,, 14
Microsoft Word - 第29回九州支部大会プログラムHP版.docx
1A-01 1 2 3 1 1 2 1 1 1 2 1 3 1 1A-02 1, 2 1, 1, 1, 1, 1, 1, 2, 1, 1 1A-03 1, 2, 3 1 1, 2, 3, 2, 3, 2, 3 1A-04 2 1, 2 1, 1, 1, 2, 2, 1 1A-05, 1A-06 sirna PEG /α- 1, 2 1, 1, 1, 1, 1, 2, 1 1A-07 1, 2, 3,
_0212_68<5A66><4EBA><79D1>_<6821><4E86><FF08><30C8><30F3><30DC><306A><3057><FF09>.pdf
- 1 -
- 1 - HIV cmc cmc - 2 - cmc() ( ) 5-3 - - 4 - (1) (2) (3) ( ) - 5 - 0537-73-2662 0537-35-2971 0548-63-1251 9 00 16 00-6 - - 7 - 2 3 4 5 6 1,328 1,848 2,368 2,888 3,408-8 - - 9 - - 10 - - 11 - 3-12 - (
第86回日本感染症学会総会学術集会後抄録（I）
κ κ κ κ κ κ μ μ β β β γ α α β β γ α β α α α γ α β β γ μ β β μ μ α ββ β β β β β β β β β β β β β β β β β β γ β μ μ μ μμ μ μ μ μ β β μ μ μ μ μ μ μ μ μ μ μ μ μ μ β
O1-1 O1-2 O1-3 O1-4 O1-5 O1-6
O1-1 O1-2 O1-3 O1-4 O1-5 O1-6 O1-7 O1-8 O1-9 O1-10 O1-11 O1-12 O1-13 O1-14 O1-15 O1-16 O1-17 O1-18 O1-19 O1-20 O1-21 O1-22 O1-23 O1-24 O1-25 O1-26 O1-27 O1-28 O1-29 O1-30 O1-31 O1-32 O1-33 O1-34 O1-35
1 911 9001030 9:00 A B C D E F G H I J K L M 1A0900 1B0900 1C0900 1D0900 1E0900 1F0900 1G0900 1H0900 1I0900 1J0900 1K0900 1L0900 1M0900 9:15 1A0915 1B0915 1C0915 1D0915 1E0915 1F0915 1G0915 1H0915 1I0915
日本医科大学医学会雑誌第8巻第1号
Xenopus laevis in situ μ μ Xenopus laevis Xenopus laevis Xenopus laevis UGT1A1 UGT1A1 IL28B KRAS UGT1A1 UGT1A128 UGT UGT1A1 UGT1A128 UGT1A1 286 UGT1A1 UGT1A1 28 6 UGT UGT UGT1A128 UGT IL28B UGT1A1
(2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( )
212009................................................ 2............................................ 115 (2009) 1... / 1 ( )........................................... 4 2... / 1 ( )......................................
n 2 + π2 6 x [10 n x] x = lim n 10 n n 10 k x 1.1. a 1, a 2,, a n, (a n ) n=1 {a n } n=1 1.2 ( ). {a n } n=1 Q ε > 0 N N m, n N a m
![n 2 + π2 6 x [10 n x] x = lim n 10 n n 10 k x 1.1. a 1, a 2,, a n, (a n ) n=1 {a n } n=1 1.2 ( ). {a n } n=1 Q ε > 0 N N m, n N a m](/thumbs/94/118912662.jpg "n 2 + π2 6 x [10 n x] x = lim n 10 n n 10 k x 1.1. a 1, a 2,, a n, (a n ) n=1 {a n } n=1 1.2 ( ). {a n } n=1 Q ε > 0 N N m, n N a m")
1 1 1 + 1 4 + + 1 n 2 + π2 6 x [10 n x] x = lim n 10 n n 10 k x 1.1. a 1, a 2,, a n, (a n ) n=1 {a n } n=1 1.2 ( ). {a n } n=1 Q ε > 0 N N m, n N a m a n < ε 1 1. ε = 10 1 N m, n N a m a n < ε = 10 1 N
ｎｓｇ０２－１３／ｋｙ０４５０５９３０１６０００３３２１０
φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W
研修コーナー
l l l l l l l Department of Obstetrics and Gynecology, Fukui Medical University, Fukui l l l l l l µ l β β l α l µ µ l l l l Department of Obstetrics and Gynecology, Gifu University School of Medicine,
NL11
information September, 2007 1 2 Japanese Association for Molecular Target Therapy of Cancer News Letter No.11 September, 2007 3 2007 4 Japanese Association for Molecular Target Therapy of Cancer News Letter
日歯雑誌（Ｈ２８・８月号）別刷り／ポスターセッション とびら
α P. gingivalis P. gingivalis αsmatgf- VEGF-A α in vitro μ Porphyromonas gingivalis in vitro Porphyromonas gingivalis β β β JBiolChem. μ μ μ β Porphyromonas gingivalis in vitro μ α β α
研修コーナー
l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
10 : 3010 : 54 1F Annex 1! 1 15:3015 : 58 1F Annex 1
4 16 1 10:0010 : 24 1F Annex 1! 2 15:0015 : 24 1F Annex 1!! 10 : 3010 : 54 1F Annex 1! 1 15:3015 : 58 1F Annex 1 ! 2 10:0010 : 28 1F Annex 1 3 15:0015 : 28 1F Annex 1 4 10:3010 : 58 1F Annex 1 1 15:3015
NL09
Information September, 2005 1 2 Japanese Association for Molecular Target Therapy of Cancer News Letter No.9 September, 2005 3 2005 4 Japanese Association for Molecular Target Therapy of Cancer News Letter
c a a ca c c% c11 c12 % s & %
c a a ca c c% c11 c12 % s & % c13 c14 cc c15 %s & % c16 c211 c21% c212 c21% c213 c21% c214 c21% c215 c21% c216 c21% c23 & & % c24 c25 c311 c312 % c31 c315 c32 c33 c34 % c35 c36 c37 c411 c N N c413 c c414c
第１４〜１５回 Ｔ細胞を介する免疫系.pptx
MBL CD8 CD4 8.1 8.2 5.20 8.3 8.4 8.5 8.6 8.7 8.8 8.9 8.10 8.18 B7 CD28 CD28 B7 CD28 8.13 2.22 NK Toll(TLR) LBP! LPS dsrna ssrna TLR1/2/6! TLR4 TLR5 TLR3 TLR7/9 CD14! JNK/p38! MyD88! IRAK! TRAF! NFκB! TNF-α
漸化式のすべてのパターンを解説しましたー高校数学の達人・河見賢司のサイト
https://www.hmg-gen.com/tuusin.html https://www.hmg-gen.com/tuusin1.html 1 2 OK 3 4 {a n } (1) a 1 = 1, a n+1 a n = 2 (2) a 1 = 3, a n+1 a n = 2n a n a n+1 a n = ( ) a n+1 a n = ( ) a n+1 a n {a n } 1,
Ethanol Preconditioning (EPC) enos(cgrp) 1 Korthuis RJ Medical Pharmacology and Physiology University of Mi
(9:40 9:50) (9:50 10:30) O-01 1 2 2 2 2 2 2 2 2 2 3 3 4 4 1 2 3 4 O-02 15-deoxy-Δ 12,14 -PGJ 2 Heme oxygenase-1(ho-1) 1 2 3 3 3 3 3 3 1 1 5 4 3 2 3 4 5 O-03 C hepcidin 1 1 1 1 1 1 1 1 1 2 2 2 2 1 2 O-04
N N 1,, N 2 N N N N N 1,, N 2 N N N N N 1,, N 2 N N N 8 1 6 3 5 7 4 9 2 1 12 13 8 15 6 3 10 4 9 16 5 14 7 2 11 7 11 23 5 19 3 20 9 12 21 14 22 1 18 10 16 8 15 24 2 25 4 17 6 13 8 1 6 3 5 7 4 9 2 1 12 13
ｎｓｇ０４－２８／ｋｙ２０８６８４３５６１０００４３０７７
δ!!! μ μ μ γ UBE3A Ube3a Ube3a δ !!!! α α α α α α α α α α μ μ α β α β β !!!!!!!! μ! Suncus murinus μ Ω! π μ Ω in vivo! μ μ μ!!! ! in situ! in vivo δ δ !!!!!!!!!! ! in vivo Orexin-Arch Orexin-Arch !!
i ii ( ) ( ) ( ) 462,891 525,032 502,164 230,636 CD CD 1 1 2 2 3 3 4 4 5 5 6 6 7 7 8 8 9 9 10 10 11 10 12 11 13 11 14 12 15 12 16 13 16 14 17 15 18 15 18 16 19 17 20 17 18 19
![Œ{Ł¶/1ŒÊ −ªfiª„¾ [ 1…y†[…W ]](/thumbs/50/26134150.jpg "Œ{Ł¶/1ŒÊ −ªfiª„¾ [ 1…y†[…W ]")
平成20年5月 協会創立50年の歩み 海の安全と環境保全を目指して 友國八郎 海上保安庁 長官 岩崎貞二 日本船主協会 会長 前川弘幸 JF全国漁業協同組合連合会 代表理事会長 服部郁弘 日本船長協会 会長 森本靖之 日本船舶機関士協会 会長 大内博文 航海訓練所 練習船船長 竹本孝弘 第二管区海上保安本部長 梅田宜弘
< > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ [ [ [ [ KULASIS
< > Introduction to Basic Organic Chemistry 1,2 [ 2 [ 10 11 12 13 14 15 [ [ [ [ KULASIS < > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ 11 12 14 15 [ [ [ [ KULASIS < > Introduction to Basic
endo.PDF
MAP 18 19 20 21 3 1173 MAP 22 700800 106 3000 23 24 59 1984 358 358 399 25 12 8 1996 3 39 24 20 10 1998 9,000 1,400 5,200 250 12 26 4 1996 156 1.3 1990 27 28 29 8 606 290 250 30 11 24 8 1779 31 22 42 9
gtf Wnt5a-Ror2 IL-8 in vitro Ozony Tron P. gingivalis SOD ELISA Location of main occluding areas and masticatory ability in patients with reduced occlusal support 12-Methacryloyloxydodecylpyridinium bromide
< > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ [ [ [ [ KULASIS
< > Introduction to Basic Organic Chemistry 1,2 [ 2 [ 10 11 12 13 14 15 [ [ [ [ KULASIS < > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ 11 12 14 15 [ [ [ [ KULASIS < > Introduction to Basic
untitled
PEDIATRIC CARDIOLOGY and CARDIAC SURGERY VOL. 22 NO. 1 (35 53) ether-à-go-go + + + + + + + + + > > + > in vivoin vitro In vivo + + + + + + + + in vivo = + = = = + + + + + + + + + + + + + + + + + + +
![かんたん操作ガイド[arrows M02]](/thumbs/39/20071242.jpg "かんたん操作ガイド[arrows M02]")
![かんたん操作ガイド[arrows RM02]](/thumbs/39/20475147.jpg "かんたん操作ガイド[arrows RM02]")
![かんたん操作ガイド[arrows M03]](/thumbs/42/22941141.jpg "かんたん操作ガイド[arrows M03]")
OABC OA OC 4, OB, AOB BOC COA 60 OA a OB b OC c () AB AC () ABC D OD ABC OD OA + p AB + q AC p q () OABC 4 f(x) + x ( ), () y f(x) P l 4 () y f(x) l P
4 ( ) ( ) ( ) ( ) 4 5 5 II III A B (0 ) 4, 6, 7 II III A B (0 ) ( ),, 6, 8, 9 II III A B (0 ) ( [ ] ) 5, 0, II A B (90 ) log x x () (a) y x + x (b) y sin (x + ) () (a) (b) (c) (d) 0 e π 0 x x x + dx e
untitled
2009518 9:109:20 A 9:2010:20 O-01 9:209:30 RNAODN CREST O-02 9:309:40 CREST O-03 9:409:50 NO O-04 9:5010:00 -- O-05 10:0010:10 闐闐 ERATO O-06 10:1010:20 DNA B 10:2011:20 O-07 10:2010:30 O-08 10:3010:40
17. (1) 18. (1) 19. (1) 20. (1) 21. (1) (3) 22. (1) (3) 23. (1) (3) (1) (3) 25. (1) (3) 26. (1) 27. (1) (3) 28. (1) 29. (1) 2
1. (1) 2. 2 (1) 4. (1) 5. (1) 6. (1) 7. (1) 8. (1) 9. (1) 10. (1) 11. (1) 12. (1) 13. (1) 14. (1) 15. (1) (3) 16. (1) 1 17. (1) 18. (1) 19. (1) 20. (1) 21. (1) (3) 22. (1) (3) 23. (1) (3) 24. 1 (1) (3)
23 15961615 1659 1657 14 1701 1711 1715 11 15 22 15 35 18 22 35 23 17 17 106 1.25 21 27 12 17 420,845 23 32 58.7 32 17 11.4 71.3 17.3 32 13.3 66.4 20.3 17 10,657 k 23 20 12 17 23 17 490,708 420,845 23
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 ( ) 24 25 26 27 28 29 30 ( ) ( ) ( ) 31 32 ( ) ( ) 33 34 35 36 37 38 39 40 41 42 43 44 ) i ii i ii 45 46 47 2 48 49 50 51 52 53 54 55 56 57 58
untitled
i ii (1) (1) (2) (1) (3) (1) (1) (2) (1) (3) (1) (1) (2) (1) (3) (2) (3) (1) (2) (3) (1) (1) (1) (1) (2) (1) (3) (1) (2) (1) (3) (1) (1) (1) (2) (1) (3) (1) (1) (2) (1) (3)
平成１８年度「商品先物取引に関する実態調査」報告書
... 1.... 5-1.... 6-2.... 9-3.... 10-4.... 12-5.... 13-6.... 15-7.... 16-8.... 17-9.... 20-10.... 22-11.... 24-12.... 27-13... 29-14.... 32-15... 37-16.... 39-17.... 41-18... 43-19... 45.... 49-1... 50-2...
国試過去問集.PDF
I 89 16 3 130 ab c AMPcAMP a 1 --- b c --- 2 --- --- 3 --- --- 4 --- --- 5 --- --- camp camp Ca 2+ β1 camp A camp camp A β1 p.156 β p.146 b. p.157 p135 (ANP) p157 c PDE-III p.157 p.157, 183 PDE C Ca PDE-III